Quick Answer
Benitec Biopharma Inc. reported Total Revenue of $59.0 thousand for fiscal year 2021.
Benitec Biopharma Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $59.0K -42.2% |
$102.0K -99.2% |
| Net Income | -$37.92M -74.3% |
-$21.75M -11.2% |
-$19.56M -7.4% |
-$18.21M -31.2% |
-$13.88M -67.8% |
-$8.27M -417.1% |
| Diluted EPS | -$1.05 +13.9% |
-$1.22 +91.4% |
-$14.12 +62.7% |
-$37.88 -1072.8% |
-$3.23 | — |
| Total Assets | $99.59M +90.8% |
$52.21M +1069.6% |
$4.46M -25.3% |
$5.97M -72.1% |
$21.38M +84.5% |
$11.59M -39.8% |
| Cash and Equivalents | $97.74M +92.2% |
$50.87M +1953.5% |
$2.48M -39.0% |
$4.06M -79.5% |
$19.77M +101.7% |
$9.80M -37.6% |
| Stockholders Equity | $97.30M +105.9% |
$47.25M +23290.1% |
$202.0K -93.0% |
$2.88M -85.6% |
$20.01M +95.4% |
$10.24M -38.3% |
| R&D Expense | $18.33M +17.4% |
$15.61M +22.2% |
$12.77M +13.3% |
$11.27M +60.6% |
$7.02M +133.9% |
$3.00M -34.3% |
| Operating Income | -$41.77M -85.7% |
-$22.49M -17.9% |
-$19.08M -6.9% |
-$17.85M -31.3% |
-$13.60M -64.2% |
-$8.28M -420.6% |
| Shares Outstanding | 25.55M +153.3% |
10.09M +503.4% |
1.67M +247.7% |
480,688 -94.1% |
8.17M +637.3% |
1.11M +29.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $0.00 | — | — |
| Net Income | December 31, 2025 | -$11.84M | -23.9% | -32.0% |
| Diluted EPS | December 31, 2025 | -$0.26 | +0.0% | -18.2% |
| Total Assets | December 31, 2025 | $190.68M | +141.2% | +98.6% |
| Cash and Equivalents | December 31, 2025 | $188.79M | +141.2% | +99.8% |
| Stockholders Equity | December 31, 2025 | $187.36M | +146.7% | +100.2% |
| R&D Expense | December 31, 2025 | $5.83M | +8.3% | +73.1% |
| Operating Income | December 31, 2025 | -$13.38M | -23.8% | -36.5% |
| Shares Outstanding | December 31, 2025 | 34.25M | +46.1% | +30.5% |
- Benitec Biopharma Inc. reported Total Revenue of $59.0 thousand for fiscal year 2021.
- Benitec Biopharma Inc. showed a decrease of -42.2% in Total Revenue compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Net Income of -$37.92 million for fiscal year 2025.
- Benitec Biopharma Inc. showed a decrease of -74.3% in Net Income compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Diluted EPS of $1.05 per share (loss) for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +13.9% in Diluted EPS compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Total Assets of $99.59 million for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +90.8% in Total Assets compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Cash and Equivalents of $97.74 million for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +92.2% in Cash and Equivalents compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Stockholders Equity of $97.30 million for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +105.9% in Stockholders Equity compared to the prior fiscal year.
- Benitec Biopharma Inc. reported R&D Expense of $18.33 million for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +17.4% in R&D Expense compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Operating Income of -$41.77 million for fiscal year 2025.
- Benitec Biopharma Inc. showed a decrease of -85.7% in Operating Income compared to the prior fiscal year.
- Benitec Biopharma Inc. reported Shares Outstanding of 26.25 million shares for fiscal year 2025.
- Benitec Biopharma Inc. showed an increase of +2.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: